CDC Recommends ZOSTAVAX®, Merck's Shingles Vaccine, For All Appropriate Adults Aged 60 And Older
                   
medicalnewstoday.com     May 19, 2008            

The U.S. Centers for Disease Control and Prevention (CDC) has adopted the unanimous recommendation of its Advisory Committee on Immunization Practices (ACIP) for the use of ZOSTAVAX® (Zoster Vaccine Live) for the prevention of shingles in adults aged 60 and older. ZOSTAVAX is the only vaccine to... [read full story]                    


View all news articles about*:
Ambulatory Care Chickenpox Child Childhood deseases Diseases Disorders Health Infections infectious Medicines Pain Patients Pharmaceuticals Remedies Schaffner Shingles Vaccines William
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Jump in measles outbreaks worries health officials...

drudgereport.com     22 mins ago   17 related          

By MIKE STOBBE, AP Medical Writer 2 hours, 5 minutes ago ATLANTA - The CDC's review found that a number of cases involved home-schooled children not required to get the vaccines. So far this year through July 30 the country has...                    

comments

India plans a MediPark

typepad.com     2 hrs ago          

Via The Economic Times: HLL, IL&FS ink MoU for medical park. Excerpt: Hindustan Latex (HLL)has signed a memorandum of understanding (MoU) with Infrastructure Leasing and Financial Services (IL&FS) for developing an integrated...                    

comments

Researchers question wide use of HPV vaccine

iht.com     3 hrs ago   62 related          

Two vaccines against a virus that can cause cervical cancer are being widely used without sufficient evidence about whether they are worth their high cost or whether they will effectively stop women from getting the disease,...                    

comments

                   

NovaRx Moves into Phase III with Cancer Vaccine Lucanix

tmcnet.com     5 hrs ago          

Hoping to repeat its Phase II success, privately held NovaRx Corp. launched a pivotal study of therapeutic vaccine Lucanix (belagenpumatucel-L) in non-small-cell lung cancer (NSCLC) patients under a special protocol assessment...                    

comments